Welcome to our dedicated page for Hinge Health news (Ticker: HNGE), a resource for investors and traders seeking the latest updates and insights on Hinge Health stock.
Hinge Health, Inc. provides a technology platform for digital health care, with a core focus on musculoskeletal conditions. The company combines an AI-powered care model, wearable devices, motion-tracking technology and access to clinicians to deliver personalized, evidence-based care for members and cost-management programs for employer, public-sector and health-plan clients.
News about Hinge Health commonly covers quarterly results and guidance, client expansion, outcomes research for chronic pain programs, and product development. Recurring updates also include the FDA-cleared Enso wearable device, the company’s Migraine Care Program, public-sector adoption of its MSK care platform, board and governance changes, and capital actions tied to its Class A common stock.
Hinge Health (NYSE: HNGE) has signed a definitive agreement to acquire Cylinder Health, a virtual-first digestive healthcare company, for $105 million in cash. The deal, subject to customary closing conditions, is expected to close in the third quarter of 2026.
According to Hinge Health, the acquisition will support an integrated Gastrointestinal (GI) Care Program expected to launch in 2027, complementing its Musculoskeletal and Migraine Care Programs. Cylinder currently has nearly 100 clients covering two million lives, partnerships with two of the three largest PBMs and three of the top five health plans by self‑insured market share, and has treated over 150,000 people with a clinically validated ROI.
Hinge Health (NYSE: HNGE) reported record Q2 2026 revenue of $212.8 million, up 53% year-over-year, with GAAP operating income of $40.4 million and non-GAAP operating income of $61.5 million (29% margin). Free cash flow rose to $99.6 million, and cash and investments reached $475.6 million.
The company signed a definitive agreement to acquire Cylinder Health for $105 million in cash, targeting an integrated Gastrointestinal Care Program expected to launch in 2027, with closing anticipated in Q3 2026 subject to customary conditions. Full-year 2026 revenue guidance was raised to $856–$860 million, and non-GAAP operating income guidance to $236–$244 million. The board also increased the share repurchase authorization, leaving $300 million available and total authorization at $496.5 million.
Hinge Health (NYSE: HNGE) announced results from a non-randomized controlled trial of its digital Fall Prevention program in 687 adults aged 65+ at risk for falls. At three months, participants using Hinge Health reported 37% fewer falls and 57% lower odds of an emergency room (ER) visit compared with a control group receiving only educational reading materials.
According to Hinge Health, intervention participants also improved physical function and control by 6.9 points more on the SF-36 Physical Functioning Scale. The program combined digital exercise therapy with dual-tasking balance exercises, education, and support from a multidisciplinary care team of physical therapists and health coaches, offering Medicare Advantage plans a potentially scalable way to address fall-related quality, cost, and access challenges.
Hinge Health (NYSE: HNGE) will release its second quarter 2026 financial results for the period ended June 30, 2026, after U.S. markets close on August 4, 2026.
The company will host an earnings conference call and live audio webcast that afternoon, with a replay available on its investor relations website.
Summary not available.
Hinge Health (NYSE: HNGE) will host its first Investor Day on June 10, 2026, at 1:00 p.m. CT, streamed via webcast. The company raised Q2 and full year 2026 guidance.
Hinge Health now expects Q2 2026 revenue of $200–$202 million with 45% year-over-year growth at the midpoint and non-GAAP operating margin of 25%. Full-year 2026 revenue is guided to $818–$824 million, up $20 million at the midpoint versus prior guidance and reflecting 40% year-over-year growth, with a non-GAAP operating margin of 27% at the midpoint. Guidance is based on non-GAAP metrics that exclude items such as stock-based compensation and acquisition-related expenses, which could significantly affect future GAAP income from operations.
Hinge Health (NYSE: HNGE) reported results from a large medical claims study of its digital musculoskeletal program, covering over 200,000 adults at nearly 1,000 employers from 2020–2024.
The analysis found average annual savings of $2,941 per member, a 3.0x ROI, rising to 3.14x in 2024, with 69% fewer surgeries, 61% fewer injections, and 68% fewer imaging scans versus matched controls. According to Hinge Health, 52% of savings came from avoided surgeries, and the methodology was independently reviewed by Howden.
Hinge Health (NYSE: HNGE) reported record Q1 2026 results: revenue $182.3M (+47% YoY) and GAAP gross margin 85%. Management raised full‑year revenue guidance by about $64M to a midpoint of $801M and expects a 26% non‑GAAP operating margin for 2026. Cash and equivalents totaled $407.1M. Q2 revenue guidance is $194M–$196M; full‑year revenue guidance is $798M–$804M. The company did not provide a reconciliation of non‑GAAP operating guidance to GAAP due to variability in stock‑based compensation and related items.
Hinge Health (NYSE: HNGE) launched a Migraine Care Program, combining its FDA-cleared Enso® wearable for rapid, drug-free migraine relief with AI-powered trigger tracking, exercise therapy, and expert-led prevention. More than 125 clients covering 2+ million people have adopted the program. Rollout begins May 2026.
Hinge Health (NYSE: HNGE) will report first-quarter 2026 financial results for the quarter ended March 31, 2026, after U.S. markets close on May 5, 2026. The company will host an earnings conference call at 1:30 p.m. PT / 4:30 p.m. ET that day, with a live audio webcast and replay available on its investor relations website.